Skip to content

XERIS PHARMACEUTICALS INC

Delisted

CIK 1346302fmd_0VKNTPPW6DKYGX4HTP6X4658NDManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2017 to Jun 30, 2021, 17 periods

Latest annual · FY2020

Millions
Total revenues
20
Gross profit
11
Operating income
(84)
Net income
(91)
Free cash flow
(80)

Latest quarter · Q2 FY2021

Millions
Total revenues
9
Gross profit
6
Operating income
(26)
Net income
(28)
Free cash flow
(20)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2017 to FY2020
+980.0%

XERIS PHARMACEUTICALS INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2020FY2019ChangeSource
Revenue$20.2 million$1.6 million+1,138.8%10-K 2021-03-09 · proof
Gross profit$11.1 million$1.1 million+892.6%10-K 2021-03-09 · proof
Operating income-$83.5 million-$122.4 million10-K 2021-03-09 · proof
Net income-$91.1 million-$125.6 million10-K 2021-03-09 · proof
Cash from operating activities-$80.6 million-$104.3 million10-K 2021-03-09 · proof
Free cash flow-$80.2 million-$103.2 million10-K 2021-03-09 · proof
Total assets$159.2 million$109 million+46%10-K 2021-03-09 · proof
Total liabilities$125.4 million$94.6 million+32.6%10-K 2021-03-09 · proof
Cash and cash equivalents$37.6 million$19.5 million+92.6%10-K 2021-03-09 · proof
What was XERIS PHARMACEUTICALS INC's revenue in fiscal 2020?
XERIS PHARMACEUTICALS INC reported revenue of $20.2 million for fiscal 2020 (the year ended Dec 31, 2020), against $1.6 million the year before (+1,138.8%). Source: the 10-K filed with the SEC on Mar 9, 2021. SEC
What was XERIS PHARMACEUTICALS INC's gross profit in fiscal 2020?
XERIS PHARMACEUTICALS INC reported gross profit of $11.1 million for fiscal 2020 (the year ended Dec 31, 2020), against $1.1 million the year before (+892.6%). Source: the 10-K filed with the SEC on Mar 9, 2021. SEC
What was XERIS PHARMACEUTICALS INC's operating income in fiscal 2020?
XERIS PHARMACEUTICALS INC reported operating income of -$83.5 million for fiscal 2020 (the year ended Dec 31, 2020), against -$122.4 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2021. SEC
What was XERIS PHARMACEUTICALS INC's net income in fiscal 2020?
XERIS PHARMACEUTICALS INC reported net income of -$91.1 million for fiscal 2020 (the year ended Dec 31, 2020), against -$125.6 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2021. SEC
What was XERIS PHARMACEUTICALS INC's cash from operating activities in fiscal 2020?
XERIS PHARMACEUTICALS INC reported cash from operating activities of -$80.6 million for fiscal 2020 (the year ended Dec 31, 2020), against -$104.3 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2021. SEC
What was XERIS PHARMACEUTICALS INC's free cash flow in fiscal 2020?
XERIS PHARMACEUTICALS INC reported free cash flow of -$80.2 million for fiscal 2020 (the year ended Dec 31, 2020), against -$103.2 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2021. SEC
What are XERIS PHARMACEUTICALS INC's total assets?
As of Dec 31, 2020, XERIS PHARMACEUTICALS INC reported total assets of $159.2 million, against $109 million a year earlier (+46%). Source: the 10-K filed with the SEC on Mar 9, 2021. SEC
What are XERIS PHARMACEUTICALS INC's total liabilities?
As of Dec 31, 2020, XERIS PHARMACEUTICALS INC reported total liabilities of $125.4 million, against $94.6 million a year earlier (+32.6%). Source: the 10-K filed with the SEC on Mar 9, 2021. SEC
What are XERIS PHARMACEUTICALS INC's cash and cash equivalents?
As of Dec 31, 2020, XERIS PHARMACEUTICALS INC reported cash and cash equivalents of $37.6 million, against $19.5 million a year earlier (+92.6%). Source: the 10-K filed with the SEC on Mar 9, 2021. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1346302&period_type=annual&limit=5"

Information only, not investment advice.